Screener
Avalo Therapeutics AVTX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's other non-current liabilities?
- Avalo Therapeutics (AVTX) reported other non-current liabilities of $0 in Q2 2026.
- How has Avalo Therapeutics's other non-current liabilities changed year-over-year?
- Avalo Therapeutics's other non-current liabilities decreased by 100.0% year-over-year, from $197K to $0.
- What is the long-term trend for Avalo Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's other non-current liabilities has grown at a -54.9% compound annual growth rate (CAGR), from $1.88M to $35K.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Avalo Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude